Distribution of 68Ga-HA-DOTATATE and 68Ga-DOTATATE in 343 Patients: Not the Same after All Abstract #1700

Introduction: For the detection of neuroendocrine tumors, 68Ga-DOTATATE was developed but its use is restricted. This led to the development of 68Ga-HA-DOTATATE. In the literature, they are described as having comparable distributions.
Aim(s): To retrospectively evaluate the distribution of 68Ga-DOTATATE and 68Ga-HA-DOTATATE in an independent patient population.
Materials and methods: All 68Ga-DOTATATE and 68Ga-HA-DOTATATE PET scans between 11-2011 and 04-2016 that were acquired 45±10 minutes post-injection were evaluated. The SUVmax and SUVmean was determined for the liver, spleen, kidney, aortic arch, pituitary-, adrenal-, parotid-, and thyroid glands. Independent sample T-testing was used to determine the difference between 68Ga-DOTATATE and 68Ga-HA-DOTATATE in each organ.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MSc Else Aalbersberg
Keywords: HA-DOTATATE

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1341 Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide before [68Ga]-DOTATATE PET/CT
Introduction: Somatostatin receptor imaging with [68Ga]-DOTATATE PET/CT has become common practice in patients with NET. Current guidelines recommend discontinuing treatment with SSAs before obtaining a [68Ga]-DOTATATE PET/CT scan. The assumption is that unlabeled somatostatin may lower the detectability of lesions.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Else Aalbersberg
Keywords: DOTATATE
#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy
Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2039 Short-Term Change in Symptoms and Adverse Events Evaluation after PRRT – First Experience after 56 Patients
Introduction: From March 2016, patients with M+ NET are treated with PRRT at the Netherlands Cancer Institute.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MSc Daphne Huizing
#2996 A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT
Introduction: The number of dosimetry studies after PRRT is increasing, yet different methodologies are used which challenge comparison or pooling of results.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2998 Inter- and Intrapatient Mean Absorbed Dose Variation and Simplification of Dosimetric Workflow after PRRT
Introduction: Post-PRRT dosimetry is not routinely performed, partly due to required multiple imaging time points. One time point imaging would reduce patient burden, and make dosimetry more applicable in the clinical settings.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing